I call it the tech story of the century: the convergence of AI and the life sciences. AI is accelerating discovery, rewriting biology and revolutionizing everything from drug development to our understanding of the cell.

It's happening right now, everywhere, all at once. And it's increasingly hard to keep track of.

Until now.

Today I'm launching BAIO, a newsletter designed to help you navigate this fast-evolving landscape. Twice a week, I'll bring you the latest in protein design, virtual cells, autonomous labs, AI-driven drug discovery, and more.

Five minutes is all you need to get up to speed on the news, deals, papers, models, and tools. What happened, why it matters, and what to look out for.

Issues are already going out. Subscribe here. It's completely free and you can unsubscribe at any time.

So why am I doing this?

Some of you know that outside of LEVITY, I cover AI as a reporter at Ny Teknik, the biggest tech news outlet in Sweden. I've been doing that since long before ChatGPT made it mainstream. And if you've been reading LEVITY for a while, you know I've argued repeatedly that AI might be the single most important accelerant for longevity science.

If I actually believe that - and I really do - then it makes sense to cover it properly. BAIO is where my AI reporting and my longevity conviction converge.

LEVITY is about defeating aging. BAIO is about the tools that will make it possible. Taken together, we're getting closer to the full picture.

Best,

/Peter